Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 3/20 | 0.34 |
| ▸ | CRBN | Q96SW2 | 3/20 | 0.34 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.33 |
| ▸ | BUB1 | O43683 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.30 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.30 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14719036 | 1.00 | DDB1 (0.34) | DDB1CRBNNR1H2BUB1USP2 | |
| SCHEMBL14731228 | 0.89 | — | — | |
| SCHEMBL14727964 | 0.78 | — | — | |
| SCHEMBL14719624 | 0.78 | USP2 (0.35) | DDB1CRBNNR1H2BUB1USP2 | |
| SCHEMBL14719623 | 0.78 | USP2 (0.35) | DDB1CRBNNR1H2BUB1USP2 | |
| SCHEMBL14719429 | 0.77 | USP2 (0.42) | DDB1CRBNNR1H2USP2SMN1; SMN2 | |
| SCHEMBL13801225 | 0.71 | USP2 (0.50) | NR1H2USP2SMN1; SMN2HDAC1GPR119 | |
| SCHEMBL31080015 | 0.71 | USP2 (0.50) | DDB1CRBNNR1H2USP2SMN1; SMN2 | |
| SCHEMBL14719640 | 0.70 | — | — | |
| SCHEMBL14718602 | 0.69 | USP2 (0.40) | DDB1CRBNNR1H2USP2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9790187-B2 | Heterocyclic compounds | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2017-10-17 | — | — | US | disclosed |
| US-9790187-B2 | Heterocyclic compounds | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2017-10-17 | — | — | US | disclosed |
| US-9790187-B2 | Heterocyclic compounds | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2017-10-17 | — | — | US | disclosed |
| US-20150307455-A1 | HETEROCYCLIC COMPOUNDS | NATIONAL SCIENCE FOUNDATION | 2015-10-29 | — | — | US | disclosed |
| US-20150307455-A1 | HETEROCYCLIC COMPOUNDS | NATIONAL SCIENCE FOUNDATION | 2015-10-29 | — | — | US | disclosed |
| US-20150307455-A1 | HETEROCYCLIC COMPOUNDS | NATIONAL SCIENCE FOUNDATION | 2015-10-29 | — | — | US | disclosed |
| US-9102683-B2 | Heterocyclic compounds | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2015-08-11 | — | — | US | disclosed |
| US-9102683-B2 | Heterocyclic compounds | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2015-08-11 | — | — | US | disclosed |
| US-9102683-B2 | Heterocyclic compounds | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2015-08-11 | — | — | US | disclosed |
| US-20130053553-A1 | HETEROCYCLIC COMPOUNDS | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2013-02-28 | — | — | US | disclosed |
| US-20130053553-A1 | HETEROCYCLIC COMPOUNDS | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2013-02-28 | — | — | US | disclosed |
| US-20130053553-A1 | HETEROCYCLIC COMPOUNDS | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2013-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150307455-A1 | HETEROCYCLIC COMPOUNDS | CYP2C8, UGT1A8, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | DDB1 3096/4885CRBN 801/4885NR1H2 1498/4885 |
| US-20130053553-A1 | HETEROCYCLIC COMPOUNDS | CYP2C8, UGT1A8, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | DDB1 3096/4885CRBN 801/4885NR1H2 1498/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.